Global Antacids Market, By Type (Sodium Antacids, Calcium Antacids, Magnesium Antacids Aluminium Antacids, Others), Indication (Gastroesophageal Reflux Disease, Heartburn, indigestion, Others), Dosage Form (Tablets, Liquid, Others), Route of Administration (Oral, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
Antacids Market Analysis and Size
The global antacids market is expected to witness significant growth during the forecast period. Growing cases of gastric ulcers, heartburn and ingestion drive the antacids market. However, easily availability of antacids OTC drugs and rising prevalence of gastric diseases will also enhance the antacids market. Researchers are developing new drugs that help boost up the market growth. Many major market players are contributing a lot in drug discovery and development. COVID-19 also had a major impact on the market growth.
Data Bridge Market Research analyses a growth rate in the global antacids market in the forecast period 2022-2029. The expected CAGR of global antacids market is tend to be around 4.4% in the mentioned forecast period. The market was valued at USD 6.93 billion in 2021, and it would grow upto USD 9.78 billion by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Antacids are the medical agents that help neutralize acid present in the stomach. Normal pH of the gastric acid is in the range of 1.5-3.5. Antacids are alkaline and contain sodium, aluminium, magnesium and calcium. Alkaline nature of antacids assists in neutralizing the gastric acid. In contrast to this, antacid’s relief the pain, inflammation and gastric acidity. It is of great importance to the healthcare sector and thus is expected to rise high in the forecast period.
Antacids Market Scope and Segmentation
2022 to 2029
2020 (Customizable to 2014 - 2019)
Revenue in USD Billion, Volumes in Units, Pricing in USD
Type (Sodium Antacids, Calcium Antacids, Magnesium Antacids Aluminium Antacids, Others), Indication (Gastroesophageal Reflux Disease, Heartburn, indigestion, Others), Dosage Form (Tablets, Liquid, Others), Route of Administration (Oral, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
Market Players Covered
Pfizer Inc (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Mylan N.V. (U.S.), Fresenius Kabi AG (Germany), Hikma Pharmaceuticals PLC (Japan), Novartis AG (Switzerland), Teva Pharmaceutical Industries Ltd. (Israel), Bristol Myers Squibb Company (U.S.) GSK Plc. (U.K.), Bayer AG (Germany), Sun Pharmaceutical Industries Ltd (India), Lupin (India), Cipla Inc (India), Aurobindo Pharma (India), Procter & Gamble (U.S.), Reckitt Benckiser Group PLC (U.K.)
Global Antacids Market Dynamics
- Rising Awareness For GERD
The rising awareness about GERD is expected to boost the market growth. As per the reports of the International Foundation for Gastrointestinal Disorders, the 19th Annual GERD Awareness Week provided information and support associated with this condition in November 2018. In addition to this, the International Foundation for Functional Gastrointestinal Disorders (IFFGD) boosts the patients who are suffering from GERD-related symptoms, to visit the physicians.
- Increase in Geriatric Population
As per the reports of the United Nations World Ageing 2019, in 2019, there were approximately 703 million people who were aged 65 years or over globally. It is expected to increase to 1.5 billion in 2050. Globally, the share of the population aged 65 years or over increased from 6% in 1990 to 9% in 2019, and almost 65% of the elderly population has to deal with acid reflux. This creates opportunity for the market.
- Increasing Demand for Retail Pharmacies
Rise in the number of antacids being delivered through retail pharmacies and surge in the number of retail pharmacies in developed countries create opportunities for the market growth. In addition to this, patients prefer retail pharmacies for purchasing drugs, as these are easily accessible.
- Rising Cases of HeartBurn
The growing prevalence of heartburn is expected to boost the market over the forecast period. As per the reports of the Medical Xpress which is a web-based medical and health news service, they stated that researchers from the University of Michigan recognized that acid reflux and heartburn affected more than 20% of the U.S. population in 2017.
- Complications of Antacids
There are some common side effects of antacids such as milkalkali syndrome and dose dependent rebound hyperacidity. Antacids which are associated with aluminium hydroxide can also cause side effects such as constipation, hypophosphatemia, aluminum poisoning, and osteomalacia. Thus, it creates hindrance to the market growth.
- High Cost
The huge expenditure of the treatment methods surely hamper the market growth.
This global antacids market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global antacids market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Global Antacids Market
The Covid-19 pandemic let a negative impact on the global antacids market because the utmost priority was given to Covid-19 patients for treatment. The COVID-19 pandemic caused a tremendous increase in antacid sales, which led to panic buying among the population who had severe medical conditions such as obesity and gastroesophageal reflux disease. In addition to this, various gastrointestinal medications were successful in treating many COVID-19 patients who were hospitalized. Thus, the COVID-19 outbreak increased the antacid market's growth globally.
Global Antacids Market Scope
The global antacids market is segmented on the basis of type, indication, dosage form, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
- Sodium Antacids
- Calcium Antacids
- Magnesium Antacids Aluminium Antacids
- Gastroesophageal Reflux Disease
Route of Administration
- Speciality Centres
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Global Antacids Market Regional Analysis/Insights
The global antacids market is analysed and market size insights and trends are provided by type, indication, dosage form, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the global antacids market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is expected to have the highest market growth due to increasing geriatric population, over use of unhealthy food and increasing initiatives taken by the pharmaceutical organizations to generate novel formulation
Asia-Pacific dominates the market due to the increasing initiatives taken by the government and pharmaceutical organizations to spread awareness.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Antacids Market Share Analysis
The global antacids market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global antacids market.
Key players operating in the global antacids market include:
- Pfizer Inc (U.S.)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Mylan N.V. (U.S.)
- Fresenius Kabi AG (Germany)
- Hikma Pharmaceuticals PLC (Japan)
- Novartis AG (Switzerland)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Bristol Myers Squibb Company (U.S.
- GSK Plc. (U.K.)
- Bayer AG (Germany)
- Sun Pharmaceutical Industries Ltd (India)
- Lupin (India)
- Cipla Inc (India)
- Aurobindo Pharma (India)
- Procter & Gamble (U.S.)
- Reckitt Benckiser Group PLC (U.K.)